Table 3 Best-achieved response rates
No of patients | CR | PR | SD | PD | RR % (95% CI) | |
|---|---|---|---|---|---|---|
Evaluable patients | 39a | 8 | 23 | 4 | 4 | 79 (64–91) |
Primary progressive | 8 | 0 | 4 | 2 | 2 | 50 (16–84) |
1st relapse | 8 | 2 | 5 | 1 | 0 | 88 (47–100) |
2nd and subsequent relapse | 23 | 6 | 14 | 1 | 2 | 87 (66–97) |
Chemosensitive | 20 | 5 | 14 | 1 | 0 | 95 (75–100) |
Chemoresistant | 19 | 3 | 9 | 3 | 4 | 63 (38–84) |
Hodgkin's lymphoma | 17 | 2 | 12 | 1 | 2 | 82 (57–96) |
DLBCL | 1 | 2 | 5 | 2 | 2 | 64 (31–89) |
Follicular lymphoma | 3 | 1 | 1 | 1 | 0 | 67 (9–99) |
Mantle cell lymphoma | 2 | 0 | 2 | 0 | 0 | 100 (16–100) |
T-cell lymphoma | 6 | 3 | 3 | 0 | 0 | 100 (29–100) |
